LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cytokine Drives Scar Formation in the Liver

By LabMedica International staff writers
Posted on 12 Jun 2017
Print article
Image: A micrograph showing cirrhosis, a form of liver fibrosis (Photo courtesy of Wikimedia Commons).
Image: A micrograph showing cirrhosis, a form of liver fibrosis (Photo courtesy of Wikimedia Commons).
Researchers have identified a cytokine that contributes strongly to the processes involved in the formation of scars in the liver, such as those that form as a consequence of hepatitis C infection.

Genetic variation in the IFNL3–IFNL4 (interferon-gamma3–interferon-gamma4) region has been shown to be associated with liver inflammation and fibrosis. Whether the IFN-gamma3 or IFN-gamma4 protein was the principle driver of this association was not known.

Investigators at the Westmead Institute for Medical Research (Sydney, Australia) had found previously that the common genetic variations associated with liver fibrosis were located on chromosome 19 between the IFNL3 and IFNL4 genes. In the current study, they analyzed liver samples from 2000 patients with hepatitis C, using state-of-the art genetic and functional analysis, to determine the specific IFNL protein responsible for liver fibrosis.

They reported in the April 10, 2017, online edition of the journal Nature Genetics that inflammation of the liver, fibrosis stage, fibrosis progression rate, hepatic infiltration of immune cells, IFN-gamma3 expression, and serum sCD163 levels (a marker of activated macrophages) were greater in individuals with the IFNL3–IFNL4 risk haplotype that produced IFN-gamma3 but did not produce IFN-gamma4. Therefore, IFN-gamma3 rather than IFN-gamma4 likely mediated IFNL3–IFNL4 haplotype–dependent liver inflammation and fibrosis.

"Liver disease is now the fifth most common cause of death in Australia, affecting six million Australians, and with significant financial cost to the health system," said senior author Dr. Jacob George, professor of hepatic medicine at the Westmead Institute for Medical Research. "We have designed a diagnostic tool based on our discoveries, which is freely available for all doctors to use, to aid in predicting liver fibrosis risk. This test will help to determine whether an individual is at high risk of developing liver fibrosis, or whether a patient's liver disease will progress rapidly or slowly, based on their genetic makeup. This important discovery will play a vital role in reducing the burden of liver disease into the future."

Related Links:
Westmead Institute for Medical Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more